We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: FDA approves first rapid-acting insulin biosimilar for sufferers with diabetes
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > FDA approves first rapid-acting insulin biosimilar for sufferers with diabetes
FDA approves first rapid-acting insulin biosimilar for sufferers with diabetes
Health

FDA approves first rapid-acting insulin biosimilar for sufferers with diabetes

Last updated: February 20, 2025 12:47 pm
Editorial Board Published February 20, 2025
Share
SHARE

The U.S. Meals and Drug Administration has accepted Sanofi-Aventis’s Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric sufferers with diabetes mellitus.

Merilog is a rapid-acting human insulin analog and the primary rapid-acting insulin biosimilar product accepted by the FDA. Administering Merilog subcutaneously 5 to 10 minutes earlier than mealtime helps enhance glycemic management in sufferers with diabetes. Each a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included on this approval.

Severe negative effects reported with Merilog embrace hypoglycemia, extreme allergic reactions, and low potassium ranges within the blood. Frequent negative effects embrace injection website reactions, itching, rash, pores and skin thickening or pitting on the injection website, weight achieve, and swelling of palms and ft.

“The FDA has now approved three biosimilar insulin products to treat diabetes,” Peter Stein, M.D., director of the Workplace of New Medicine within the FDA Middle for Drug Analysis and Analysis, mentioned in an company press launch.

“Today’s approval highlights our continued efforts to improve the efficiency of the biosimilar approval process to help support a competitive marketplace and increase options for costly treatments, like insulin. Increasing access to safe, effective and high-quality medications at potentially lower cost remains a continued priority for the FDA.”

Quotation:
FDA approves first rapid-acting insulin biosimilar for sufferers with diabetes (2025, February 20)
retrieved 20 February 2025
from https://medicalxpress.com/information/2025-02-fda-rapid-insulin-biosimilar-patients.html

This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

You Might Also Like

Hepatitis C therapy just isn’t reaching some at-risk populations

‘An excessive amount of occurring’: Autistic adults overwhelmed by non-verbal social cues

Key mind protein might maintain solutions for reminiscence loss and neurodegenerative ailments

Early-onset neonatal sepsis linked to childhood epilepsy

Energy in numbers: Examine finds small group teaching reduces charges of doctor burnout by almost 30%

TAGGED:approvesbiosimilarDiabetesFDAInsulinpatientsrapidacting
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Knicks gamers embrace the Christmas spirit by giving again
Sports

Knicks gamers embrace the Christmas spirit by giving again

Editorial Board December 28, 2024
Liz Cheney, Front and Center in the Jan. 6 Hearings, Pursues a Mission
A General Fights to Destigmatize Mental Health Issues: ‘There’s a Shame if You Show Weakness’
Alex Jones and Donald Trump: A Fateful Alliance Draws Scrutiny
Aged neurological sufferers are open to in-home distant monitoring, finds examine

You Might Also Like

RFK Jr. cancels key US well being panel assembly with out warning, elevating issues
Health

RFK Jr. cancels key US well being panel assembly with out warning, elevating issues

July 11, 2025
Examine exhibits how brain-to-computer ‘electroceuticals’ will help restore cognition
Health

Examine exhibits how brain-to-computer ‘electroceuticals’ will help restore cognition

July 11, 2025
Merely ‘sprinkling’ a fluorescent probe can shortly present lively mind synapses
Health

Merely ‘sprinkling’ a fluorescent probe can shortly present lively mind synapses

July 11, 2025
Mathematical mannequin reveals how people retailer narrative recollections utilizing ‘random timber’
Health

Mathematical mannequin reveals how people retailer narrative recollections utilizing ‘random timber’

July 11, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?